SEC Comment Letter 0000000000-23-005241 to HilleVax, Inc. (HLVX) (CIK 0001888012)
HilleVax, Inc. (HLVX) (CIK 0001888012)
Date: May 16, 2023 · CIK: 0001888012 · Accession: 0000000000-23-005241
AI Filing Summary & Sentiment
File numbers found in text: 333-271892
Letter
United States securities and exchange commission logo May 16, 2023 Robert Hershberg, M.D., Ph.D. Chief Executive Officer HilleVax, Inc. 75 State Street, Suite 100 - #9995 Boston, MA 02109 Re:HilleVax, Inc. Registration Statement on Form S-3 Filed May 12, 2023 File No. 333-271892 Dear Robert Hershberg: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew T. Bush, Esq.
Show Raw Text
United States securities and exchange commission logo
May 16, 2023
Robert Hershberg, M.D., Ph.D.
Chief Executive Officer
HilleVax, Inc.
75 State Street, Suite 100 - #9995
Boston, MA 02109
Re:HilleVax, Inc.
Registration Statement on Form S-3
Filed May 12, 2023
File No. 333-271892
Dear Robert Hershberg:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew T. Bush, Esq.